TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Journal:

Journal of Clinical Oncology

Published:

2025-07-31

DOI:

10.1200/jco-25-01651

Affiliations:

22

Authors:

23

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	7.000000	0.30
Associated Medical Professionals, United States of America (USA)	1.000000	0.04
Colorado Urology, United States of America (USA)	1.000000	0.04
Netherlands Cancer Institute (NKI), Netherlands	1.000000	0.04
Urologie Neandertal, Germany	1.000000	0.04
University Hospital of Münster (UKM), WWU, Germany	1.000000	0.04
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), United States of America (USA)	1.000000	0.04
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.04
Hospital de Jerez de la Frontera, Spain	1.000000	0.04
IRCCS Regina Elena National Cancer Institute (IRE), Italy	1.000000	0.04
State University of New York Upstate Medical University (SUNY Upstate Medical University), United States of America (USA)	1.000000	0.04
USC Norris Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
Hospital Universitario 12 de Octubre, Spain	1.000000	0.04
NYU Langone Health, United States of America (USA)	1.000000	0.04
Yokohama City University Medical Center, YCU, Japan	1.000000	0.04
Bichat-Claude Bernard Hospital, France	1.000000	0.04
IRCCS San Raffaele Hospital (HSR), Italy	0.500000	0.02
Vita-Salute San Raffaele University (UniSR), Italy	0.500000	0.02

Interested in Oncology and Carcinogenesis?